Northwestern Mutual Wealth Management Co. Purchases 2,609 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Northwestern Mutual Wealth Management Co. increased its holdings in Thermo Fisher Scientific Inc. by 2.3%, purchasing an additional 2,609 shares in the first quarter, bringing the total to 116,310 shares valued at $57.88 million.
• Numerous institutional investors, including GAMMA Investing LLC and Nuveen LLC, have significantly increased their stakes in Thermo Fisher, with GAMMA lifting its holdings by an astonishing 60,610.9%.
• Thermo Fisher announced a quarterly dividend of $0.43 per share to be paid on October 15, reflecting an annualized yield of 0.3% and a modest dividend payout ratio of 9.95%.

Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 2.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 116,310 shares of the medical research company's stock after purchasing an additional 2,609 shares during the quarter. Northwestern Mutual Wealth Management Co.'s holdings in Thermo Fisher Scientific were worth $57,876,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Revolve Wealth Partners LLC raised its stake in Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after purchasing an additional 20 shares during the period. Port Capital LLC raised its stake in Thermo Fisher Scientific by 1.6% during the 4th quarter. Port Capital LLC now owns 1,385 shares of the medical research company's stock valued at $721,000 after purchasing an additional 22 shares during the period. Clark Capital Management Group Inc. grew its holdings in Thermo Fisher Scientific by 0.5% during the 4th quarter. Clark Capital Management Group Inc. now owns 4,445 shares of the medical research company's stock valued at $2,312,000 after buying an additional 23 shares in the last quarter. Monograph Wealth Advisors LLC grew its holdings in Thermo Fisher Scientific by 0.3% during the 4th quarter. Monograph Wealth Advisors LLC now owns 8,656 shares of the medical research company's stock valued at $4,507,000 after buying an additional 23 shares in the last quarter. Finally, Intergy Private Wealth LLC grew its holdings in Thermo Fisher Scientific by 5.8% during the 1st quarter. Intergy Private Wealth LLC now owns 419 shares of the medical research company's stock valued at $208,000 after buying an additional 23 shares in the last quarter. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Trading Down 0.0%

Shares of TMO stock traded down $0.01 on Wednesday, reaching $488.47. 1,294,754 shares of the company's stock were exchanged, compared to its average volume of 2,461,173. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $627.88. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $184.45 billion, a PE ratio of 28.25, a P/E/G ratio of 2.62 and a beta of 0.74. The company's fifty day simple moving average is $446.71 and its 200 day simple moving average is $455.47.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. During the same period last year, the company earned $5.37 EPS. Thermo Fisher Scientific's quarterly revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.95%.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on TMO shares. UBS Group raised their price target on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a report on Thursday, July 24th. Evercore ISI cut their price target on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a report on Tuesday, July 8th. William Blair started coverage on Thermo Fisher Scientific in a report on Monday, August 18th. They set an "outperform" rating for the company. Barclays raised their price target on Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an "equal weight" rating in a report on Thursday, July 24th. Finally, HSBC reiterated a "hold" rating and issued a $510.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Sixteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $593.00.

Insider Buying and Selling

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the sale, the executive vice president directly owned 22,367 shares of the company's stock, valued at $10,735,712.66. The trade was a 1.76% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $500.96, for a total value of $5,009,600.00. Following the sale, the chief executive officer directly owned 115,174 shares of the company's stock, valued at approximately $57,697,567.04. This trade represents a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 28,896 shares of company stock valued at $13,603,438 over the last three months. 0.33% of the stock is owned by corporate insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.